Earnings ·
Candel Therapeutics reported a net loss of $38.9 million for the quarter ended June 30, 2026, compared to a $4.8…
CADLCandel Therapeutics, Inc.
Candel Therapeutics reported a net loss of $38.9 million for the quarter ended June 30, 2026, compared to a $4.8 million loss in the prior year period. Cash and cash equivalents stood at $201.6 million as of June 30, 2026, sufficient to fund operations into Q1 2028. The company plans to submit a Biologics License Application for aglatimagene besadenovec in localized prostate cancer in Q4 2026. Pivotal phase 3 data showed a 39% improvement in disease-free survival with the drug plus radiotherapy versus radiotherapy alone. Additionally, Candel activated its first trial site for the AURORA phase 3 trial of aglatimagene in non-squamous NSCLC and appointed Mark Sims as Chief Commercial Officer. The company operates in the biopharmaceutical industry, developing multimodal immunotherapies to improve outcomes for patients with cancer.